PFIZER REPORTS SECOND-QUARTER 2015 RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Pfizer (PFE) PT Lifted to $41 at BMO Capital on Sum-of-the-Parts
July 29, 2015 7:30 AM EDTBMO Capital analyst Alex Arfaei reiterated an Outperform rating and boosted his price target on Pfizer (NYSE: PFE) to $41.00 (from $39.00) following Q2 results, saying the sum of the parts is looking better and said a split is becoming more likely.
Arfaei commented, "Now $41/share based on the weighted average of DCF ($37,... More
Pfizer (PFE) Tops Q2 EPS by 4c
July 28, 2015 7:01 AM EDTPfizer (NYSE: PFE) reported Q2 EPS of $0.56, $0.04 better than the analyst estimate of $0.52. Revenue for the quarter came in at $11 billion versus the consensus estimate of $11.42 billion.
Raised Midpoints of 2015 Financial Guidance Ranges for Reported Revenues by $500 Million and Reported and Adjusted(2) Diluted EPS by $0.03 and $0.04, Respectively, Due to Strong Performance to Date and Improved Business Outlook
EXECUTIVE COMMENTARY
Ian Read, Chairman and Chief Executive Officer, stated, Our second-quarter and year-to-date financial performance is the result of continued business... More
